GLYMPA® 25/5 Tablets combine Empagliflozin (25 mg), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Linagliptin (5 mg), a dipeptidyl peptidase-4 (DPP-4) inhibitor. This dual-action therapy is designed to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin works by reducing renal glucose reabsorption, thereby increasing urinary glucose excretion, while Linagliptin enhances incretin hormone activity, stimulating insulin release and reducing glucagon levels. Together, they provide complementary mechanisms to lower blood glucose and reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.
